| 周禄科.经导管动脉化疗栓塞术联合静脉注射重组人血管内皮抑制素治疗肝癌 45例[J].安徽医药,2022,26(4):689-692. |
| 经导管动脉化疗栓塞术联合静脉注射重组人血管内皮抑制素治疗肝癌 45例 |
| Effect of TACE combined with intravenous injection of recombinant human endostatin in the treatment of 45 cases of liver cancer |
| |
| DOI：10.3969/j.issn.1009-6469.2022.04.011 |
| 中文关键词: 肝肿瘤 内皮抑素类 化学栓塞，治疗性 血管内皮生长因子类 干扰素诱导跨膜蛋白 3 微小 RNA |
| 英文关键词: Liver neoplasms Endostatins Chemoembolization, therapeutic Vascular endothelial growth factors Interferon-induced transmembrane protein micro RNA |
| 基金项目: |
|
| 摘要点击次数: 971 |
| 全文下载次数: 354 |
| 中文摘要: |
| 目的研究经导管动脉化疗栓塞术( TACE)联合重组人血管内皮抑制素注射液(恩度)对原发性肝癌(简称“肝癌”)病人疗效及血清微小 RNA(miR-122、miR-21)、干扰素诱导跨膜蛋白 3(IFITM3)水平的影响。方法选取德阳市人民医院 2014年 8月至 2016年 10月期间收治的 90例肝癌病人，按照数字随机表法分为对照组和观察组，每组 45例。对照组采用腹腔镜肝切除术( LLR)治疗 +TACE，观察组在对照组基础上使用恩度，并于术后治疗 6周。对比两组病人治疗后的 3年复发率、生存率以及中位生存时间，监测治疗前后血清微小 RNA、IFITM3水平，以及治疗过程中不良反应情况。结果随访 3年，观察组、对照组分别有 13例( 28.89%)、 23例( 51.11%)复发，中位生存时间分别为 42.24个月( 95%CI:33.47~53.27)、 27.63个月( 95%CI: 22.64~31.83)，死亡数分别为 15例( 33.33%)、 25例( 55.56%)差异有统计学意义( P<0.05)。治疗后两组病人血清 miR-21水平显著降低，而 miR-122显著增加，两组血清微小 RNA水平差异显，著( P<0.05)。治疗后，两组病人血清 IFITM3、血管内皮生长因子( VEGF)水平均显著降低，其中观察组病人血清 IFITM3、VEGF水平显著低于对照组［( 301.35±32.12)ng/L比( 472.35±36.25) ng/L、(101.35±10.12)μg/L比( 142.35±11.78)μg/L，P<0.05］。观察组不良反应发生率 35.56%，与对照组( 37.78%)相比差异无统计学意义( P>0.05)。结论腹腔镜肝癌切除术后采用 TACE术联合恩度治疗原发性肝癌病人疗效显著，可显著改善血清微小 |
| 英文摘要: |
| Objective To study the effect of transcatheter arterial chemoembolization (TACE) combined with recombinant humanendostatin injection (Endu) on patients with liver cancer and its effect on serum microRNA (miR-122, miR-21) and interferon-induced transmembrane protein 3 (IFITM3).Methods Ninety patients with liver cancer who were admitted to Deyang People's Hospital fromAugust 2014 to October 2016 were selected and assigned into a control group and an observation group according to the random tablemethod, with 45 cases in each group. The control group was treated with laparoscopic hepatectomy (LLR)+TACE, while the observationgroup was treated with Endostar on the basis of the control group and was treated for 6 weeks after operation. The 3-year recurrencerate, survival rate, median survival time, the level of micro RNA and IFITM3 and adverse reaction were compared between the twogroups.Results Follow-up for 3 years, there were 13 cases (28.89%) and 23 cases (51.11%) palindromia in the observation group andthe control group, the median survival time was 42.24 months (95% CI:33.47-53.27), 27.63 months (95% CI:22.64-31.83), and the num ber of deaths was 15 cases (33.33%) and 25 cases (55.56%), respectively, with statistical significance (P<0.05). After treatment, the lev el of miR-21 in the two groups decreased and the level of miR-122 increased significantly, and the serum miRNA levels of the two groups were significantly different (P<0.05). The level of serum IFITM3 and VEGF in both groups decreased significantly after treat ment, and the level of serum IFITM3 [(301.35±32.12) ng/L vs. (472.35±36.25) ng/L], VEGF [(101.35±10.12) μg/L vs. (142.35±11.78) μg/L] in the observation group was significantly lower than that in the control group (P<0.05). The incidence of adverse reactions in theobservation group was 35.56%, and there was no significant difference compared with the control group (37.78%) (P>0.05).Conclu sion After laparoscopic liver resection, TACE combined with Endostat in the treatment of patients with primary liver cancer has a sig nificant curative effect. It can significantly improve serum microRNA levels and reduce IFITM3 and VEGF protein levels, thereby re ducing the recurrence rate and mortality, and improving the treatment effect. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
